NO974179L - Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi - Google Patents

Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi

Info

Publication number
NO974179L
NO974179L NO974179A NO974179A NO974179L NO 974179 L NO974179 L NO 974179L NO 974179 A NO974179 A NO 974179A NO 974179 A NO974179 A NO 974179A NO 974179 L NO974179 L NO 974179L
Authority
NO
Norway
Prior art keywords
gene therapy
recombinant viruses
cholesterol acyltransferase
viruses expressing
lecithin
Prior art date
Application number
NO974179A
Other languages
English (en)
Other versions
NO974179D0 (no
Inventor
Patrice Denefle
Nicolas Duverger
Martine Latta-Mahieu
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO974179D0 publication Critical patent/NO974179D0/no
Publication of NO974179L publication Critical patent/NO974179L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
NO974179A 1995-03-14 1997-09-10 Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi NO974179L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502943A FR2731710B1 (fr) 1995-03-14 1995-03-14 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
PCT/FR1996/000381 WO1996028553A1 (fr) 1995-03-14 1996-03-12 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
NO974179D0 NO974179D0 (no) 1997-09-10
NO974179L true NO974179L (no) 1997-09-10

Family

ID=9477007

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974179A NO974179L (no) 1995-03-14 1997-09-10 Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi

Country Status (15)

Country Link
US (1) US20010014319A1 (no)
EP (1) EP0815239A1 (no)
JP (1) JPH11501518A (no)
KR (1) KR19980703008A (no)
AU (1) AU711381B2 (no)
BR (1) BR9607757A (no)
CA (1) CA2214010A1 (no)
CZ (1) CZ286897A3 (no)
FR (1) FR2731710B1 (no)
HU (1) HUP9801214A3 (no)
IL (1) IL117466A0 (no)
NO (1) NO974179L (no)
SK (1) SK124897A3 (no)
WO (1) WO1996028553A1 (no)
ZA (1) ZA961998B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353957T1 (de) * 1995-11-09 2007-03-15 Us Gov Health & Human Serv Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
EP0973914B1 (en) 1997-04-11 2006-12-13 Takeda Pharmaceutical Company Limited Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
EP1428041A4 (en) * 2001-06-19 2007-01-17 Paxflow Holdings Pte Ltd LOCATION, COMMUNICATION AND PURSUIT SYSTEMS
NZ537072A (en) 2002-06-18 2006-12-22 Eisai Co Ltd Primary cultured adipocytes for gene therapy to which a foreign gene has been transferred
WO2007143724A2 (en) * 2006-06-07 2007-12-13 Reddy Us Therapeutics, Inc. Compositions and methods to enhance reverse cholesterol transport
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
JPWO2008108344A1 (ja) * 2007-03-02 2010-06-17 セルジェンテック株式会社 Ｌｃａｔ欠損症の遺伝子治療用細胞並びに遺伝子治療用細胞組成物
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
TW201823467A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 犬腺病毒載體
AR109540A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Moléculas promotoras para expresar antígenos virales
EP3515480A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New swine influenza vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) * 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique

Also Published As

Publication number Publication date
JPH11501518A (ja) 1999-02-09
FR2731710B1 (fr) 1997-04-30
CZ286897A3 (en) 1997-12-17
NO974179D0 (no) 1997-09-10
ZA961998B (en) 1996-09-26
EP0815239A1 (fr) 1998-01-07
HUP9801214A3 (en) 2000-08-28
WO1996028553A1 (fr) 1996-09-19
MX9706569A (es) 1997-11-29
SK124897A3 (en) 1998-02-04
US20010014319A1 (en) 2001-08-16
AU5008296A (en) 1996-10-02
CA2214010A1 (fr) 1996-09-19
BR9607757A (pt) 1999-01-26
IL117466A0 (en) 1996-07-23
HUP9801214A2 (hu) 1998-08-28
AU711381B2 (en) 1999-10-14
FR2731710A1 (fr) 1996-09-20
KR19980703008A (ko) 1998-09-05

Similar Documents

Publication Publication Date Title
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
ZA949104B (en) Recombinant viruses and their use in gene therapy
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
NO950939D0 (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL181695A0 (en) Methods for cultivating cells and propagating viruses
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
IL111682A0 (en) Recombinant viruses and their use in gene therapy
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
NO973230D0 (no) Nye peptider, deres fremstilling og anvendelse
NO20013101D0 (no) Ytre overflateproteiner, deres gener og deres anvendelse
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
NO990303L (no) Lipidbindende proteiner og deres terapeutiske og diagnostiske anvendelse
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy
CA2475337A1 (en) Methods for cultivating cells and propagating viruses
FR2726575B1 (fr) Virus recombinants, preparation et utilisation en therapie genique
GB9501978D0 (en) Nucleic acids, proteins and their use in therapy
IT241431Y1 (it) Flacone e/o involucro biuso
DE69634993D1 (de) Verwendung von hyaluronan in gentherapie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application